dslogo
azlogo

DESTINY-Breast07: Patient Demographics (Results from Part 2/Modules 0 [T-DXd monotherapy] and Module 2 [T-DXd + pertuzumab] as of December 22, 2023 DCO) 

Patient Demographics

Patient Demographics11. André F, Hamilton EP, Loi S, et al. DESTINY-Breast07: dose-expansion and analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. Abstract 1009. Presented at American Society of Clinical Oncology (ASCO) Congress; May 31-June 4, 2024; Chicago, Illinois

Patient Demographics and Disease Characteristics in Part 2/Modules 0 and 2.11. André F, Hamilton EP, Loi S, et al. DESTINY-Breast07: dose-expansion and analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. Abstract 1009. Presented at American Society of Clinical Oncology (ASCO) Congress; May 31-June 4, 2024; Chicago, Illinois
Characteristics

Module 0

T-DXd monotherapy

n=75

Module 2

T-DXd + pertuzumab

n=50

Age, mean (range), year57.0 (33.0-80.0)56.5 (24.0-75.0)
Female, n (%)74 (98.7)a50 (100)

Race, n (%)

   White

   Asian

   Black or African American

   Not reported

   Other

 

52 (69.3)

20 (26.7)

2 (2.7)

1 (1.3)

0

 

37 (74.0)

12 (24.0)

0

0

1 (2.0)

HER2 status, n (%)

   IHC 3+b

   IHC 2+/ISH+

   IHC 2+

 

60 (80.0)

14 (18.7)

1 (1.3)

 

41 (82.0)

9 (18.0)

0

HR status, n (%)

   Positivec

   Negative

 

47 (62.7)

28 (37.3)

 

34 (68.0)

16 (32.0)

Disease status, n (%)

   Recurrentd

   De novoe


27 (36.0)

48 (64.0)


20 (40.0)

30 (60.0)

ECOG PS, n (%)

   0

   1

 

49 (65.3)

26 (34.7)

 

37 (74.0)

13 (26.0)

aMale, n=1; bRegardless of ISH status; cDefined as ER and or PR-positive (ER or PR >1%); dDefined as previously treated in the (neo)adjuvant setting with chemotherapy, HER2-targeted agents or endocrine therapy and includes previously treated HER2-negative patients who now have HER2-positive disease in the metastatic setting; eDefined as no prior systemic therapy in the (neo)adjuvant setting with chemotherapy, HER2-targeted agents, or endocrine therapy.
Prior HER2-targeted therapy in patients with recurrent mBC11. André F, Hamilton EP, Loi S, et al. DESTINY-Breast07: dose-expansion and analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. Abstract 1009. Presented at American Society of Clinical Oncology (ASCO) Congress; May 31-June 4, 2024; Chicago, Illinois
n (%)

Module 0

T-DXd monotherapy

(n=27)

Module 2

T-DXd + pertuzumab

(n=20)

Trastuzumab14 (51.9)13 (65.0)
Pertuzumab4 (14.8)2 (10.0)
T-DM12 (7.4)0
Patient Disposition11. André F, Hamilton EP, Loi S, et al. DESTINY-Breast07: dose-expansion and analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. Abstract 1009. Presented at American Society of Clinical Oncology (ASCO) Congress; May 31-June 4, 2024; Chicago, Illinois
 

Module 0

T-DXd monotherapy

(n=75)

Module 2

T-DXd + pertuzumab

(n=50)

Median duration of follow up, months23.925.3
Ongoing study treatment, n (%)47 (62.7)28 (56.0)

Discontinued treatment, %

   Objective disease progression

   Adverse event

   Withdrawal by patient

   Other

      Deatha

28 (37.3)

10 (13.3)

7 (9.3)

6 (8.0)

5 (6.7)

2 (2.7)

22 (44.0)

8 (16.0)

9 (18.0)

2 (4.0)

3 (6.0)

1 (2.0)

aIncludes death while on treatment with investigational product; investigators did not specifically record a reason for discontinuation of investigational product.

Abbreviations

AE = adverse event

;

DCO = data cut-off

;

ECOG = Eastern Cooperative Oncology Group

;

ER = estrogen receptor

;

HER2 = human epidermal growth factor receptor 2

;

HR = hormone receptor

;

IHC = immunohistochemistry

;

ISH = in-situ hybridization

;

PR = progesterone receptor

;

PS = performance status

;

T-DM1 = trastuzumab emtansine

;

T-DXd = trastuzumab deruxtecan

References

1. André F, Hamilton EP, Loi S, et al. DESTINY-Breast07: dose-expansion and analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. Abstract 1009. Presented at American Society of Clinical Oncology (ASCO) Congress; May 31-June 4, 2024; Chicago, Illinois

Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy. 

To help us improve our content for health care professionals, please take this short survey.

Feedback Survey

Document ID: 325e86bc-2a1f-401a-b8d6-fa304896a85b
Last updated: 14-February-2023

©2023 AstraZeneca. All rights reserved.